CAR-T cell therapy targeting IL-1RAP for high-risk MDS
Part of Blood & lymphatic clinical trials.
This trial is testing a new type of therapy, called CAR-T cells, that are designed to target and attack a specific marker on MDS cells. It is for people with high-risk MDS when standard treatments aren't working or at first diagnosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of MDS.
- Your MDS must be classified as high-risk (based on a specific risk score like IPSS-M).
- You must be either newly diagnosed, or have had standard treatments stop working (like hypomethylating agents or stem cell transplant).
- You must not have acute myeloid leukemia, another active cancer, or any condition that prevents a bone marrow test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy, ARD103, for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or is not responding to treatment. It aims to see if this therapy can help control the disease.
This study tests a newer type of immune therapy called CAR-T cells in people with blood cancers like AML or MDS that have come back or not responded to prior treatments. The therapy is designed to find and destroy cancer cells that have specific markers (CD33, CD123, or CLL-1), with the goal of putting the cancer into remission.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
This trial tests a personalized cancer treatment called CAR-T therapy. It uses your own immune cells, which are modified in a lab to fight your specific type of blood cancer, and then given back to you. The goal is to see if this treatment is safe and feasible when produced locally.
This trial tests a new type of CAR-T cell therapy that targets two proteins on leukemia cells (called CLL1 and CD33). The goal is to help people with acute myeloid leukemia that has relapsed or not responded to standard treatments.
Hear when a new Myelodysplastic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.